Harmony Biosciences (NASDAQ:HRMY) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. The 12-month price targets, analyzed by analysts, offer insights with an average target of $52.67, a high estimate of $56.00, and a low estimate of $52.00. Marking an increase of 1.29%, the current average surpasses the previous average price target of $52.00. Diving into Analyst Ratings…